{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-044549","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.829766+00:00","generated_at":"2026-05-24T05:55:35.189386+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acrivon reports ACR-368 35% ORR in refractory endometrial cancer; deprioritizes ovarian/bladder","bullets":["Preliminary cash, cash equivalents and ST investments ~$184.6M as of Dec 31, 2024; runway into 2027.","ACR-368 BM+ endometrial cancer: 35% confirmed ORR, 80% DCR in 20 heavily pretreated patients (median 2 prior lines).","In BM+ patients refractory to last prior therapy (ORR 0%), ACR-368 achieved 33% ORR and 75% DCR.","Company deprioritized ovarian and bladder cancers; shifting resources to ACR-368 in endometrial cancer and ACR-2316.","ACR-2316 Phase 1: cleared DL2 without safety concerns; initial clinical activity observed in a patient at DL3."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-044549","json":"https://secwatch.observer/filing/0000950170-25-044549.json","markdown":"https://secwatch.observer/filing/0000950170-25-044549.md","text":"https://secwatch.observer/filing/0000950170-25-044549.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025044549/0000950170-25-044549-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025044549/acrv-20250325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:55:35.189386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}